Lunasin

Research-Grade

Lunasin is a 43-amino-acid peptide originally isolated from soybean cotyledons by Alfredo Galvez and colleagues at UC Berkeley in 1999. It is the first dietary peptide identified with a defined epigenetic mechanism of action — specifically, inhibition of histone acetyltransferase (HAT) activity. By preventing acetylation of core histones H3 and H4, lunasin suppresses the transcription of genes involved in cell proliferation and transformation, which underpins its cancer chemopreventive properties. The peptide contains three functional domains: a helical region for chromatin binding, an RGD (Arg-Gly-Asp) motif that mediates integrin receptor interactions, and a poly-aspartic acid C-terminal tail that binds deacetylated histones. Preclinical evidence for lunasin spans multiple cancer models. In vitro, lunasin inhibits chemical carcinogen-induced transformation in mouse fibroblasts (C3H 10T1/2) and human breast cancer cell proliferation. In skin cancer models, topical lunasin application reduced tumor incidence by 70% in DMBA/TPA-treated mice. Lunasin has also demonstrated activity against non-small cell lung cancer, colon cancer, and leukemia cell lines. Its RGD motif enables it to bind alpha-v-beta-3 and alpha-5-beta-1 integrins on immune cells, enhancing natural killer (NK) cell cytotoxicity and dendritic cell activation. A 2012 study showed lunasin potentiated NK cell killing of cancer cells by 2-4 fold through integrin-mediated signaling. Beyond oncology, lunasin has demonstrated cholesterol-lowering effects in both animal models and a small human trial. A 2010 randomized controlled trial (n=120) found that lunasin-enriched soy protein reduced LDL cholesterol by an additional 4.5% compared to standard soy protein over 8 weeks. The mechanism involves suppression of HMG-CoA reductase expression through epigenetic modulation. Lunasin is naturally present in soybeans, barley, wheat, and other seeds at concentrations of 0.5-8 mg per gram of soy protein, making it one of the few bioactive peptides with meaningful dietary exposure. Lunasin is commercially available as a dietary supplement in the US, typically derived from soy protein extraction. Its oral bioavailability has been confirmed in human pharmacokinetic studies — intact lunasin peptide is detectable in plasma after oral administration of soy-derived preparations. The peptide survives gastric digestion partially intact, likely due to its compact structure and the protective effect of the food matrix. Clinical development remains in early stages, with most evidence coming from preclinical models and small human studies. No phase 2 or phase 3 clinical trials for cancer endpoints have been completed.